circRNA basic information
circBase ID: hsa_circ_0060927
Name: hsa_circ_CYP24A1
Synonym: circCYP24A1
Host Gene: CYP24A1
Genomic location(hg19): chr20:52773707-52788209:-
Genomic location(hg38): chr20:54157168-54171670:-
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
0008315
MONDO name: prostate cancer
Disease details: prostate cancer / PCa
Disease DO ID:
10283
Disease MeSH ID:
D011471
Disease NCIt ID:
C7378
Disease ICD11 ID:
-
Disease OMIM ID:
-
Species: Human
Species details: Homo sapiens
Tissue specimen:

PCa biopsy tissues; PCa tissue specimens; xenograft tumors

Cell lines:

DU145-DR; DU145; 22Rv1; HEK293T

In vivo animal model:

cell line-derived xenograft

circRNA-disease information
Expression pattern:
UP
Associated gene: ALDH1A3, AGO2, PI3K/AKT/mTOR signaling pathway
Associated microRNA: miR-1301-3p
Biological function: promotes docetaxel resistance and suppresses docetaxel chemosensitivity; inhibits DTX-induced apoptosis and reduces G2/M phase arrest
Molecular mechanism: circCYP24A1 acts as a miRNA sponge for miR-1301-3p to upregulate ALDH1A3 and activate PI3K/AKT/mTOR signaling, promoting docetaxel resistance
Biological pathway or process:

PI3K/AKT/mTOR (promotes); apoptosis (inhibits); cell cycle (other); chemoresistance (promotes); ceRNA regulation (promotes)

Detected method:
Q
H
S
Validation methods:

RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; TUNEL; ROC Analysis; Bioinformatics Analysis

Clinical significance:

circCYP24A1 expression was an independent risk factor to predict DTX response and could be a biomarker to predict DTX response

Description:

circCYP24A1 is upregulated in docetaxel-resistant prostate cancer and reduces DTX chemosensitivity in vitro and in vivo. It promotes chemoresistance by sponging miR-1301-3p to upregulate ALDH1A3 and activate PI3K/AKT/mTOR signaling, and its expression predicts DTX response in a patient cohort.

Confidence score:

0.8932

Other information
Title:

circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3.

Journal: Biomarker research
Published: 2022
PubMed ID: 35831872
Study type:

combined biological and clinical study

Data availability: available from the corresponding author on reasonable request
Code availability: -